Recent Updates
Recently added Catalysts

GWP42003

Phase 2

Dyslipidemias | Small molecule | Cardiovascular |Jazz Pharmaceuticals plc|Last Updated: Oct 18, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment62

FDA Designations

No designations recorded

Clinical trial landscape

GWP42003 · 3 trials · 5 indications

Phase 2 3
NCT02006628A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic DisorderSchizophrenia
COMPLETED88 Analytics
NCT01562314A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)Ulcerative Colitis
COMPLETED60 Analytics
NCT01217112GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II DiabetesDyslipidemias
COMPLETED62 Analytics
PHASE2COMPLETED
A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
SchizophreniaUnlock trial analytics
PHASE2COMPLETED
A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)
Ulcerative ColitisUnlock trial analytics
PHASE2COMPLETED
GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes
DyslipidemiasUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline To End Of Treatment (Day 43) In Positive And Negative Syndrome Scale (PANSS) Total Score
Day 1 through Day 43

The PANSS was a 30-item medical scale completed by a trained rater that assessed the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. The PANSS Total score was derived from the sum of the 30 items, which were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total score is the summed total for each of the PANSS positive symptom ('P'), negative symptom ('N'), general psychopathology symptom ('G') scores and could range from 30 to 210 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

Percentage Of PANSS Total Score Responders At End Of Treatment (Day 43)
Day 1 through Day 43

The percentage of PANSS treatment responders, defined as participants with ≥20% improvement in PANSS Total score between baseline and End of Treatment, is presented. The percentage of participants was calculated by dividing the number of participants with a ≥20% improvement in PANSS Total score (yes) by the total number of participants.

Change From Baseline To The End Of Treatment (Day 43) In PANSS 'P' Score
Day 1 through Day 43

The PANSS 'P' scale measured the severity of positive symptoms, including delusions, conceptual disorganization, hallucinations, hyperactivity, grandiosity, suspiciousness/persecution, and hostility. Individual items were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total 'P' score could range from 7 to 49 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

Change From Baseline To The End Of Treatment (Day 43) In PANSS 'N' Score
Day 1 through Day 43

The PANSS 'N' scale measured the severity of negative symptoms, including blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. Individual items were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total 'N' score could range from 7 to 49 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

Change From Baseline To The End Of Treatment (Day 43) In PANSS 'G' Score
Day 1 through Day 43

The PANSS 'G' scale measured the severity of general psychopathology symptoms, including somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgement and insight, disturbance of violation, poor impulse control, preoccupation, and active social avoidance. Individual items were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total 'G' score could range from 16 to 112 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

Change From Baseline To The End Of Treatment (Day 43) In The Scale For The Assessment Of Negative Symptoms (SANS)
Day 1 through Day 43

The SANS assessed 5 symptom complexes to obtain clinical ratings of negative symptoms in participants with schizophrenia or related psychotic disorder. Symptom complexes were affective blunting, alogia (impoverished thinking), avolition/apathy, anhedonia/asociality, and disturbance of attention. Assessments were conducted on a 6-point scale (0 = not at all; 5 = severe). The total score could range from 0 to 125 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

Change From Baseline To The End Of Treatment (Day 43) In The Clinical Global Impression Severity Scale (CGI-S)
Day 1 through Day 43

The CGI-S was a 7-point scale that required the clinician to rate the severity of a participant's illness at the time of assessment, relative to the clinician's past experience of participants who had the same diagnosis. Considering total clinical experience, participants were assessed on severity of mental illness at the time of rating on the following scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill. Lower scores equated to milder severity of symptoms, that is, closer to psychologically normal.

Clinical Global Impression Improvement Scale (CGI-I) Values At Day 8 And End Of Treatment (Day 43)
Day 8 through Day 43

The CGI-I was a 7-point scale that required the clinician to assess how much a participant's illness had improved or worsened relative the first assessment at the beginning of the intervention. This was rated on the following scale: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. Lower scores equated to improvement of symptoms.

Change From Baseline To The End Of Treatment (Day 43) In Brief Assessment Of Cognition In Schizophrenia (BACS) Score
Day 1 through Day 43

The BACS was an instrument used to assess the aspects of cognition found to be most impaired and most strongly correlated with outcome in participants with schizophrenia or related psychotic disorder. The BACS consisted of 6 domains: verbal memory (score range 0 to 75), working memory (score range 0 to 28), motor speed (score range 0 to 100), verbal fluency (score \> 0, with no set maximum value), attention and speed of information processing (score range 0 to 110), and executive functions (score range 0 to 22). A score was obtained for each of the 6 domains. A composite summary score was then calculated as the arithmetic mean of the unweighted scores from the 6 domains. While there was not an upper limit on the composite score, overall, an increase in score was indicative of an improvement in cognition.

Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT
Baseline to End of Treatment (EOT) (10 weeks) or Early Termination (ET)

The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores, each of which is assessed using a 0 to 3 scale. Sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); Physician's Global Assessment of Illness Severity (PGAS): 0 = none, 1 = mild, 2 = moderate, and 3 = severe.

Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT - PP Analysis
Baseline to EOT (10 weeks) or ET

The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores, each of which is assessed using a 0 to 3 scale. Sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate, and 3 = severe.

The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment
Baseline (Day 1) and End of treatment (Day 92)

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum High Density Lipoprotein cholesterol. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

Secondary Endpoints

Distribution On The PGAS At EOT
EOT (10 weeks) or ET
Distribution On The PGAS At EOT - PP Analysis
EOT (10 weeks) or ET
Change From Baseline To EOT In The PGAS Score
Baseline to EOT (10 weeks) or ET
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
GWP42003 1000 milligrams (mg)/dayACTIVE_COMPARATORParticipants received GWP42003 (100 mg/milliliter \[mL\]), 5 mL twice daily (BID) administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
PlaceboPLACEBO_COMPARATORParticipants received placebo (0 mL cannabidiol \[CBD\]), volume matched to the 5 mL BID dose level, administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
GWP42003EXPERIMENTALGWP42003 was administered orally at a dose of 50 mg up to 250 mg, BID, in the fasted state in the morning and evening, for 10 weeks. Following randomization, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 500 mg, and maintained this dose for the rest of the treatment period. Participants were then followed for 1 week.
GWP42004 and placeboACTIVE_COMPARATORContains GWP42004 5 mg and placebo (excipients only)
1:1 GWP42003 : GWP42004ACTIVE_COMPARATORContains 5 mg each of GWP42003 and GWP42004
20:1 GWP42003 : GWP42004ACTIVE_COMPARATORContains 100 mg GWP42003 and 5 mg GWP42004
GWP42003 and placeboACTIVE_COMPARATORContains 100 mg GWP42003 and placebo (excipients only)

Interventions

NameTypeDescription
PlaceboDRUGPlacebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
GWP42003DRUGGWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
GWP42004DRUG5 mg capsules, PO, BD, 91 days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites14

Inclusion Criteria (all must be fulfilled): * Participant gave written informed consent for participation in the study and did not require involuntary treatment. * Participant was male or female aged 18 to 65 years. * Participant was able (in the investigator's opinion) and willing to comply with a...

Countries:PolandRomaniaUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about GWP42003

What is GWP42003 used for?

GWP42003 is an investigational small molecule being studied for dyslipidemias, schizophrenia, fatty liver, and ulcerative colitis. It has completed Phase 2 trials in these indications, including as adjunctive therapy in schizophrenia and related psychotic disorders.

Who makes GWP42003?

GWP42003 is being developed by Jazz Pharmaceuticals plc, traded on NASDAQ under the ticker JAZZ. The company has conducted Phase 2 clinical trials of this investigational drug across multiple indications.

What phase is GWP42003 in?

GWP42003 is in Phase 2 clinical development. All four completed trials were Phase 2 studies, and the drug remains investigational, not yet approved by regulatory authorities.

What clinical trials is GWP42003 in?

GWP42003 has completed four Phase 2 trials: NCT01217112 in dyslipidemias and type 2 diabetes, NCT01284634 in fatty liver, NCT01562314 in ulcerative colitis, and NCT02006628 in schizophrenia. These trials were conducted in the United Kingdom, Poland, and Romania.

Is GWP42003 the same as GWP42004?

GWP42003 is distinct from GWP42004. One trial, NCT01217112, studied GWP42003 and GWP42004 together and alone in type 2 diabetes, indicating they are separate investigational compounds being evaluated individually and in combination.